Liraglutide vs Semaglutide
Comparing first-generation daily GLP-1 agonist liraglutide with next-generation weekly semaglutide for diabetes and weight management.
Last updated: January 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Liraglutide
Dossier overview
Semaglutide
Dossier overview
Overview
Liraglutide and semaglutide are both GLP-1 receptor agonists developed by Novo Nordisk, representing successive generations of incretin therapy. Liraglutide requires daily injection, while semaglutide offers weekly dosing and greater efficacy. Both are FDA-approved for type 2 diabetes and obesity.
This comparison illustrates the evolution of GLP-1 therapeutics and helps understand the practical differences between these related medications.
Key Facts
| Aspect | Liraglutide | Semaglutide |
|---|---|---|
| Developer | Novo Nordisk | Novo Nordisk |
| Approval Year | 2010 (diabetes) | 2017 (diabetes) |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Brands (Diabetes) | Victoza | Ozempic |
| Brands (Obesity) | Saxenda | Wegovy |
Structure Comparison
| Aspect | Liraglutide | Semaglutide |
|---|---|---|
| Homology to GLP-1 | 97% | 94% |
| Amino Acid Changes | 1 (Lys34→Arg) | 2 (Ala8→Aib, Lys34→Arg) |
| Fatty Acid Chain | C16 (palmitic acid) | C18 diacid chain |
| Half-life | ~13 hours | ~165 hours (~7 days) |
Why Semaglutide Lasts Longer
- Aib substitution at position 8 resists DPP-4 degradation
- C18 fatty acid chain enhances albumin binding
- Slower release from albumin reservoir
- Allows weekly dosing vs. daily
Efficacy Comparison
Weight Loss
| Metric | Liraglutide 3mg | Semaglutide 2.4mg |
|---|---|---|
| Trial | SCALE | STEP 1 |
| Mean Weight Loss | -8.0% | -14.9% |
| ≥5% Weight Loss | 63% | 86% |
| ≥10% Weight Loss | 33% | 69% |
| ≥15% Weight Loss | 14% | 50% |
Note: Semaglutide achieves nearly double the weight loss of liraglutide in clinical trials.
HbA1c Reduction
| Metric | Liraglutide 1.8mg | Semaglutide 1mg |
|---|---|---|
| Reduction | -1.1% to -1.5% | -1.5% to -1.8% |
| Target under 7% | ~60% | ~70-80% |
Head-to-Head Trial (SUSTAIN 10)
Direct comparison in type 2 diabetes:
| Outcome | Semaglutide 1mg | Liraglutide 1.2mg |
|---|---|---|
| HbA1c Change | -1.7% | -1.0% |
| Weight Change | -5.8 kg | -1.9 kg |
| Superiority | Yes | — |
Administration Comparison
| Aspect | Liraglutide | Semaglutide (Injectable) |
|---|---|---|
| Injections/month | ~30 | 4 |
| Flexibility | Any time of day | Same day each week |
Oral Semaglutide Option
| Aspect | Liraglutide | Oral Semaglutide (Rybelsus) |
|---|---|---|
| Route | Injection only | Oral tablet |
| Food Restriction | None | Fasting required |
Cardiovascular Evidence
| Aspect | Liraglutide | Semaglutide |
|---|---|---|
| CV Trial | LEADER | SUSTAIN-6, SELECT |
| MACE Reduction | 13% | 26% (SUSTAIN-6), 20% (SELECT) |
| CV Death | 22% reduction | Significant reduction |
| FDA CV Indication | Yes | Yes |
Cardiovascular Summary
Both medications have demonstrated cardiovascular benefit:
| Outcome | Liraglutide | Semaglutide |
|---|---|---|
| Heart Attack | Reduced | Reduced |
| Stroke | Reduced | Reduced |
| CV Death | Reduced | Reduced |
| Heart Failure | Neutral | Preliminary benefit |
Side Effect Comparison
Gastrointestinal Effects
| Effect | Liraglutide | Semaglutide |
|---|---|---|
| Nausea | 30-40% | 30-45% |
| Vomiting | 10-15% | 15-25% |
| Diarrhea | 15-20% | 20-30% |
| Constipation | 10-15% | 15-20% |
Note: Semaglutide’s higher efficacy comes with somewhat higher GI side effect rates.
Discontinuation Rates
| Reason | Liraglutide | Semaglutide |
|---|---|---|
| GI Side Effects | 6-10% | 7-10% |
| Overall | 8-12% | 8-12% |
Other Side Effects
| Effect | Liraglutide | Semaglutide |
|---|---|---|
| Injection Site | Occasional | Less frequent (weekly) |
| Hypoglycemia | Low (monotherapy) | Low (monotherapy) |
| Pancreatitis | Rare | Rare |
| Gallbladder Events | Elevated risk | Elevated risk |
Indications Comparison
| Indication | Liraglutide | Semaglutide |
|---|---|---|
| Type 2 Diabetes | Victoza (FDA) | Ozempic (FDA) |
| Obesity (BMI ≥30) | Saxenda (FDA) | Wegovy (FDA) |
| Overweight + Comorbidity | Saxenda (FDA) | Wegovy (FDA) |
| CV Risk Reduction | Victoza (FDA) | Ozempic (FDA) |
Cost Comparison
| Factor | Liraglutide | Semaglutide |
|---|---|---|
| List Price | ~$1,000-1,400/month | ~$900-1,350/month |
| Insurance Coverage | Established | Expanding |
| Generic Available | No | No |
Note: Actual costs vary significantly based on insurance, pharmacy, and dosage.
Patient Selection Considerations
Liraglutide May Be Preferred When:
- Daily routine is already injection-based
- Shorter half-life desired (e.g., pregnancy planning)
- Established comfort with the medication
- Insurance/cost factors favor it
Semaglutide May Be Preferred When:
- Weekly dosing strongly preferred
- Maximum efficacy is priority
- Oral option desired (Rybelsus)
- Greater weight loss needed
Evidence Quality
| Factor | Liraglutide | Semaglutide |
|---|---|---|
| Trial Quality | High | High |
| Sample Size | Large | Large |
| Long-term Data | 10+ years | 5+ years |
| Real-World Evidence | Extensive | Growing rapidly |
| CV Outcomes | LEADER (proven) | SELECT (proven) |
Summary
| Factor | Liraglutide | Semaglutide |
|---|---|---|
| Weight Loss | ~8% | ~15% |
| HbA1c Reduction | ~1.3% | ~1.7% |
| CV Benefit | Proven | Proven |
| Oral Option | No | Yes (Rybelsus) |
| Track Record | Longer | Shorter |
Key Takeaways
- Semaglutide is more effective: Nearly double the weight loss, better glycemic control
- Semaglutide is more convenient: Weekly vs. daily dosing
- Both have CV benefit: Proven cardiovascular risk reduction
- Semaglutide has oral option: Rybelsus available for those preferring tablets
- Liraglutide has longer track record: More years of real-world data
- GI effects similar: Both cause nausea, vomiting, diarrhea
- Cost is similar: Both remain expensive branded medications
- Same developer: Both from Novo Nordisk, representing generational evolution
This comparison is for educational purposes only. Both medications are FDA-approved. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.